Deputy Governor of Shanghai Pudong New District Government, and Others Investigated Medicilon

On the afternoon of January 4, 2021, Wu Qiang, member of the Party Leadership Group and Deputy District Mayor of Shanghai Pudong New Area Government, Li Xiaoliang, Deputy Director of the Pudong Science and Economic Commission, Wu Jun, Deputy Director of Zhangjiang Administration Bureau, and Wang Kairong, Deputy General Manager of Zhangjiang Group On the first day of investigation in Shanghai Medicilon, Medicilon founder & CEO Dr. Chunlin Chen, Executive Director of Pharmacodynamics Department Dr. Dong Wenxin, Director of Corporate Affairs Department Zhou Nanmei and others introduced the company to the leaders who visited and guided Happening.

Deputy District Mayor Wu Qiang and others observed the company’s new technology and application research and development progress on the spot, had a deep understanding of industry development trends, and listened to company needs and suggestions. On the first day of the New Year’s work, the leaders of Medicilon conducted research and guidance, and the leaders fully expressed their deep concern and sympathy for the development of Medicilon.

Shanghai Medicilon was established in 2004. It is a comprehensive biomedical research and development service company dedicated to providing a full range of preclinical new drug research services for global pharmaceutical companies, research institutions and scientific researchers. Dr. Chen and others expressed their gratitude to Vice Mayor Wu Qiang for his visit and guidance, and said Medicilon will focus on innovation, serve attentively, strengthen cooperation, and help development!
Wu Qiang, Member of the Party Leadership Group and Deputy District Mayor of Shanghai Pudong New Area Government, Li Xiaoliang, Deputy Director of Pudong New Area Science and Economic Commission, Wu Jun, Deputy Director of Zhangjiang Administration Bureau, Wang Kairong, Deputy General Manager of Zhangjiang Group, etc. investigated Medicilon

About Medicilon

Medicilon (stock code: 688202) was established in 2004 and is headquartered in Shanghai. It is committed to providing a full range of preclinical new drug research services for global pharmaceutical companies, research institutions and scientific researchers. Medicilon’s one-stop integrated service helps customers accelerate the development of new drugs with strong project management and more efficient and cost-effective R&D services. The services cover the entire process of preclinical new drug research in medicine, including drug discovery, pharmaceutical research and clinical trials. Pre-research. Medicilon grows together with high-quality customers at home and abroad, and provides new drug research and development services to more than 700 customers around the world. Medicilon will continue to base itself on a global perspective, gather Chinese innovation, and contribute to human health!

contact us
Email: marketing@medicilon.com
Phone: +86 (21) 5859-1500